NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Bambusa Therapeutics

Bambusa Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://bambusatx.com/

Last Round

Series A

Extension

Nov 17, 2025

Est. Valuation

$555M

Total Funding Raised

$145M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Bambusa Therapeutics is a biotechnology company that develops bispecific antibodies for the treatment of immunological and inflammatory disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalbispecific antibodiesclinical trialsdrug discoverybiotechtherapeutic developmentclinical-stage biotechdrug pipelinepharmaceutical R&DbiologicsPhase I trialsdrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bambusa Therapeutics Comparables

Compare Bambusa Therapeutics with similar companies based on industry and business-model similarity.

Bambusa Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Bambusa Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionNov 17, 2025
Series AFeb 14, 2025
SeedSep 9, 2024
Series A ExtensionNov 17, 2023

Bambusa Therapeutics Investors

Notable investors and investment history

Bambusa Therapeutics investors
InvestorRounds
Redmile GroupSeries A, Series A Extension
SalviaSeries A, Series A Extension, Seed
Janus Henderson GroupSeries A, Series A Extension
ADAR1 Capital ManagementSeries A, Series A Extension
RA Capital ManagementSeries A Extension, Series A
Kohlberg Kravis RobertsSeries A
渶策资本Series A, Series A Extension, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 25, 2026

    Grew 18% QoQ from 17 to 20 employees.

  • Apr 25, 2026

    Grew 36% QoQ, from 14 to 19 employees.

Bambusa Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Bambusa Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Bambusa Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range20
Year Founded2024
Last FundingNov 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.